Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.73 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.64 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.56 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 4/20 | 0.54 |
| ▸ | RXRB | P28702 | 4/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784246 | 1.00 | BCL2 (0.73) | BCL2ACMSDAOC3TSHRSMN1; SMN2 | |
| SCHEMBL5519447 | 0.87 | KMO (0.63) | BCL2ACMSDPRKCIRXRARXRB | |
| SCHEMBL3208925 | 0.85 | BCL2 (0.55) | BCL2ACMSDAOC3TSHRSMN1; SMN2 | |
| SCHEMBL14496864 | 0.84 | BCL2 (0.71) | BCL2AOC3TRIM24TRIM33RXRA | |
| SCHEMBL12894973 | 0.84 | BCL2 (1.00) | BCL2AOC3TRIM24TRIM33RXRA | |
| Hydrochloric Acid SCHEMBL5548244 | 0.83 | BCL2 (0.69) | BCL2AOC3TRIM24TRIM33RXRA | |
| SCHEMBL30108284 | 0.82 | PRKCI (0.70) | BCL2ACMSDAOC3TSHRPRKCI | |
| SCHEMBL30066684 | 0.82 | KMO (0.72) | BCL2ACMSDTSHRTRIM24TRIM33 | |
| SCHEMBL249824 | 0.82 | PRKCI (0.70) | BCL2ACMSDAOC3TSHRPRKCI | |
| SCHEMBL16166011 | 0.82 | KMO (0.72) | BCL2ACMSDTSHRTRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | BCL2 3819/4885ACMSD 3684/4885AOC3 2139/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | BCL2 2466/4885ACMSD 3054/4885AOC3 2841/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | BCL2 2542/4885ACMSD 1112/4885AOC3 1045/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | BCL2 3819/4885ACMSD 3684/4885AOC3 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.